Inflammasome activation and pulmonary viral loads define two distinct clinical outcomes in COVID-19.

Keyla S.G. de Sá[1], Luana A. Amaral[1], Camila C.S. Caetano[1], Amanda Becerra[1], Sabrina S. Batah[2], Isadora M. de Oliveira[1], Letícia S. Lopes[1], Leticia Almeida[1], Samuel Oliveira[1], Danilo Tadao Wada[3], Marcel Koenigkam-Santos[3], Ronaldo B. Martins[1], Roberta R. C. Rosales[1], Eurico Arruda[1], Alexandre T Fabro[2], Dario S. Zamboni[1*].

[1]Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, 14049-900, Brazil.

[2]Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, 14049-900, Brazil.

[3]Departamento de Imagens Médicas, Hematologia e Oncologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, 14049-900, Brazil.

*Correspondence:

Email: dszamboni@fmrp.usp.br

Abstract

Inflammasome activation is associated with disease severity in patients who are infected with SARS-CoV-2 and influenza viruses, but the specific cell types involved in inflammasome activation, as well as the balance of inflammasome activation versus viral replication in COVID-19 exacerbation and the induction of patient death, are unknown. In this study, we assessed lung autopsies of 47 COVID-19 and 12 influenza fatal cases and examined the inflammatory profiles and inflammasome activation; additionally, we correlated these factors with clinical and histopathological patient conditions. We observed an overall stronger inflammasome activation in lethal cases of SARS-CoV-2 compared to influenza and found a different profile of inflammasome-activating cells during these diseases. In COVID-19 patients, inflammasome activation is mostly mediated by macrophages and endothelial cells, whereas in influenza, type I and type II pneumocytes contribute more significantly. An analysis of gene expression allowed for the classification of COVID-19 patients into two different clusters. Cluster 1 (n=16 patients) died with higher viral loads and exhibited a reduced inflammatory profile than Cluster 2 (n=31 patients). Illness time, mechanical ventilation time, pulmonary fibrosis, respiratory functions, histopathological status, thrombosis, and inflammasome activation significantly differed between the two clusters. Our data demonstrated two distinct profiles in lethal cases of COVID-19, thus indicating that the balance of viral replication and inflammasome-mediated pulmonary inflammation may lead to different clinical conditions, yet both lead to patient death. An understanding of this process is critical for decisions between immune-mediated or antiviral-mediated therapies for the treatment of critical cases of COVID-19.

Introduction

Influenza viruses and epidemic coranaviruses are the most frequent viral agents of

acute respiratory distress syndrome (ARDS). Between 2019 and 2021, there were

35,000,000 symptomatic cases of influenza with approximately 20,000 deaths in the

United States [1] and more than 255,000,000 confirmed cases and 5,127,000 deaths

caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

worldwide [2]. Severe ARDS is characterized by major pulmonary involvement,

respiratory distress, systemic thrombosis, and death [3-5].

The activation of the NLRP3 inflammasome has been described both in influenza [6-

10] and SARS-CoV-2 infections [11-16], and this process contributes to excessive

inflammation and poor clinical outcome. The recruitment of immune cells to the

lungs of infected individuals culminates in the excessive release of cytokines that

cause structural damage to the lungs [17, 18]. Moreover, the major reported lung

pathologies of severe COVID-19 include diffuse alveolar damage (DAD), acute

fibrinoid organizing pneumonia (AFOP), and chronic interstitial pneumonia [3-5, 19].

NLRP3 inflammasome activation also occurs in the lung parenchyma of these

patients [16, 20]. For influenza, the major reported lung pathologies include diffuse

alveolar damage in addition to necrotizing bronchitis, bronchiolitis, and fibrosis [21].

However, it is still unknown as to how the activation of this immune complex is

related to the exacerbated inflammatory process in human lung parenchyma cells

during viral infections such as influenza and SARS-CoV-2.

In the present study, postmortem lung tissue samples from 47 fatal COVID-19

patients and 12 fatal influenza patients were examined for inflammasome activation

and gene expression; in addition, these factors were correlated with the clinical

conditions of the patients to understand the molecular mechanisms underlying the

pathological processes that lead to the death of these patients. We demonstrated

the presence of robust inflammasome activation in the lungs of patients infected

with SARS-CoV-2 and influenza virus and defined the specific cell types that

contribute to inflammasome activation in response to these viruses. An analysis of

gene expression in pulmonary tissues allowed for the classification of COVID-19

patients into two different clusters (one cluster with patients who died with higher

viral loads and reduced inflammatory profiles, which opposes the data from the

other cluster). Our data indicated that inflammasome activation by different cell

types contributes to the pathology of influenza and COVID-19, thus indicating that a

distinct balance in viral replication and inflammation may culminate with patient

death in COVID-19.

Materials and Methods

Samples

Minimally invasive autopsy was performed on 47 patients diagnosed with SARS-

CoV-2 at the Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da

Universidade de São Paulo, Brazil (Ribeirão Preto, SP, Brazil) from April to July,

2020, by Serviço de Patologia (SERPAT). Minimally invasive autopsy was done at

bedside through post-mort surgical lung biopsy by a matching 14-gauge cutting

needle (Magnum Needles, Bard) and a biopsy gun (Magnum, Bard). Moreover, a 3

cm incision on the more affected side of the chest between the fourth and fifth ribs

were also used to provide extra lung tissue. All tissue samples were embedded in

paraffin and fixed in formalin (Formalin-Fixed Paraffin- Embedded, FFPE). Lung

tissue from autopsies of patients diagnosed with Influenza (n=12) of patients who

died between the years 2012 to 2020 and biopsy of Lung Adenocarcinoma patients

(n=5) were obtained from SERPAT. The project was approved by the Research

Ethics Committee of FMRP/USP under protocol nº 4,089 .567.

Immunohistochemistry (IHC)

Tissue section in paraffin blocks were tested by immunohistochemistry using

antibodies for the detection of NLRP3 (clone D2P5E; 1:3,000; Cell Signaling), ASC

(1:2,000; Adipogen AL177), SFTPC (1:200, ThermoFisher PA5-71680), CD68

(1:200, Dako M0814), CD34 (1:500, Zeta Z2063ML), PDPN (1:200, ThermoFisher

14-9381-82), THY-1 (1:300, Sigma SAB4200497), Vimentin (1:200, Sigma V2258),

Anti-cleaved N-terminal GSDMD (1:200, Abcam ab215203), Caspase-1 (1:200,

Abcam ab207802), IL-1β (1:200, Abcam ab2105) for the *in situ* detection of these

inflammasome proteins. The Sequential Immunoperoxidase Labeling and Erasing

(SIMPLE) technique was used to evaluate all markers in the same tissue, as

previously published [22]. Briefly, after incubation with primary antibody (overnight at

4ºC), slides were incubated with immune peroxidase polymer anti-mouse

visualization system (SPD-125, Spring Bioscience, 345 Biogen) and with

chromogen-substrate AEC peroxidase system kit (SK-4200, 346 Vector

Laboratories, Burlingame, CA). After high resolution scanning by a VS120 Olympus

microscope, the coverslips were removed in PBS and the slides were dehydrated in

an ethanol gradient to 95% ethanol. The slides were incubated in a series of ethanol

to erase the AEC marking. Afterwards the slides were rehydrated and the

antibodies were removed with an incubation for 2 min in a solution of 0.15 mM 351

$KMnO4/0.01$ M H_2SO_4, followed immediately by a wash in distilled water. Tissues

were then remarked.

Immunofluorescence

The slides were incubated with the primary antibodies, rabbit anti-human NLRP3

mAb (clone D2P5E; 1:300; Cell Signaling), rabbit anti-human ASC polyclonal

antibody (1:200; Adipogen AL177), SFTPC (1:200, ThermoFisher PA5-71680),

CD64 (1:200, Biolegend 139304), CD34 (1:500, Zeta Z2063ML), PDPN (1:200,

ThermoFisher 14-9381-82), overnight at 4ºC and with the secondary antibodies

Goat anti-mouse Alexa fluor-647 (Invitrogen) or Goat anti-rabbit Alexa fluor-594

(Invitrogen). Images were acquired by the Axio Observer system combined with the

LSM 780 confocal device microscope at 63x magnification (Carl Zeiss).

Histological Evaluation

Paraffin-embedded lung tissues sections (3 μm) were stained by standard

hematoxylin and eosin (H&E). Morphological lung injury patterns were evaluated by

specialized pulmonary pathologists (ATF) blinded to clinical history. They were

classified as absent or present with its extent of lung injury area by 5% cut-offs in

Fibrosis, Organizing Pneumonia (OP), Acute Fibrinous and Organizing Pneumonia

(AFOP), Diffuse Alveolar Damage (DAD), Cellular Pneumonitis, Thrombus

Formation.

RNA extraction

RNA from influenza samples and respective controls was extracted from Paraffin-embedded tissue samples. Samples were cut into 3 sections of 10 μm, and placed in RNase-free, 2.0-ml Eppendorf tubes. Sections were deparaffinized by incubation in 0.8 ml of xylene at 37°C for 5 minutes. The samples were then centrifuged, the supernatant was removed, and fresh xylene was added for a second incubation. After deparaffinization and centrifugation, sections were washed with 0.8 ml ethanol, air-dried for several minutes, and resuspended in 25 μl of 20 mg/ml Proteinase K (Gibco BRL, Gaithersburg, MD) plus 720 μl of a digestion buffer with the following final concentrations: 20mM TRIS-HCl pH8, 10mM EDTA pH8, 1% of SDS. Samples were vortexed and incubated overnight at 55°C at 400 rpm. A second 25 μl aliquot of 20 mg/ml Proteinase K was then added, followed by vortexing and incubation for 2h at 55°C. RNA was obtained by extraction with 1 mL of Trizol reagent and purification was performed according to the manufacturer's instructions. Total RNA from fresh lung tissue of SARS-CoV-2 patients and respective controls was obtained using Trizol reagent and purification was performed according to the manufacturer's instructions. The RNA was quantified by spectrophotometry in a NanoDrop 2000c spectrophotometer. The concentration was adjusted to 1 μg/μL, and the RNA was stored at −70 ∘C until reverse transcription.

Real-Time Polymerase Chain Reaction for inflammatory genes

For inflammatory genes qPCR the total RNA was transcribed into complementary DNA (cDNA) using a High-Capacity cDNA Reverse Transcription kit (without an inhibitor) according to the protocol provided by the manufacturer (Thermo Fisher, Carlsbad, CA, USA). The reaction was prepared in a final volume of 20.0 μL containing 4.2 μL of H_2O, 2.0 μL of buffer, 2.0 μL of random primers, 0.8 μL of dNTP Mix (100 mM), 1.0 μL of reverse transcriptase (RT) enzyme and 1 μL of RNA (1 ug/μL). The solution was then placed into a thermocycler with the following program: 25 ∘C for 10 min, 37 ∘C for 120 min and 85 ℃ for 5 min. The real-time PCR was performed in 96-well plates using Sybr Green reagents (Applied Biosystems, Waltham, MA, USA) and a Quant studio real-time PCR system (Applied Biosystems, Foster City, CA, USA). The real time-RT-PCR was carried out in a total volume of 20 μl on a 96-well MicroAmp Fast Optical plate (Applied Biosystems). Each well contained 10 μl SYBR Green qPCR Master Mix (Thermofisher), 1 μl of each primer (**Supplementary Table 1**), 2 μl cDNA (20 ng) and 7 μl RNase free water using the following protocol: initial denaturation at 95°C

for 10 min, 40 cycles of denaturation at 95°C for 15 s followed by
annealing/extension at 60°C for 60 s. Each PCR was followed by a dissociation
curve analysis between 60-95°C. The Ct values were analyzed by the comparative
Ct (ΔΔCt) method and normalized to the endogenous control GAPDH. Fold
difference was calculated as $2^{-\Delta\Delta Ct}$

Real-Time Polymerase Chain Reaction for Viral RNA

Detection and quantification of SARS-CoV-2 genes was performed with primer-
probe sets for 2019-nCoV_N2 and gene E, according to US Centers for Disease
Control and Prevention [23] and Charité group protocols [24]. The genes evaluated (N2,
E, and RNase-P housekeeping gene) were tested by one-step real-time RT-PCR
using total nucleic acids extracted with TRIzol (Invitrogen). All real-time PCR assays
were done on a Quant studio real-time PCR system (Applied Biosystems, Foster
City, CA, USA). A total of 70 ng of RNA was used for genome amplification, adding
specific primers (20 µM), and probe (5 µM), and with TaqPath 1-Step quantitative
RT-PCR Master Mix (Applied Biosystems), with the following parameters: 25°C for 2
min, 50°C for 15 min, and 95°C for 2 min, followed by 45 cycles of 94°C for 5 s and
60°C for 30 s. Primers used were the following: N2 forward: 5′-
TTACAAACATTGGCCGCAAA-3′, N2 reverse: 5′-GCGCGACATTCCGAAGAA-3′;
N2 probe: 5′-FAM-ACAATTTGCCCCCAGCGCTTCAG-BHQ1-3′ [23]; E forward: 5′-
ACAGGTACGTTAATAGTTAATAGCGT-3′, E reverse: 5′-
ATATTGCAGCAGTACGCACACA-3′; E probe: 5′-AM-
ACACTAGCCATCCTTACTGCGCTTCG-BHQ-1-3′ [24]; RNase-P forward: 5′-
AGATTTGGACCTGCGAGCG-3′, RNase-P reverse: 5′-
GAGCGGCTGTCTCCACAAGT-3′; and RNase-P probe: 5′-FAM-
TTCTGACCTGAAGGCTCTGCGCG-BHQ-1-3′ [23]. A plasmid of N2 protein and E
protein was used for a standard curve construction for viral load quantification.

Chest computed tomography images acquisition and evaluation

Chest x-radiography (CXR) and computed tomography (CT) exams were performed
as part of the routine clinical evaluation. Chest radiographies were performed in
conventional equipment, mainly in the anteroposterior incidence. CT images were
performed in multidetector scanners (Brilliance CT Big Bore 16 - Philips, Holland, or
Aquilion Prime 160 - Toshiba, Japan), using similar protocols for the acquisition of
high-resolution images of the lungs [25]. Patients were scanned in the supine position

without the administration of intravenous contrast media. Typical acquisition
parameters were: 120 kVp tube voltage, 100–140 ref mAs [26], 0.3–0.7 s gantry
rotation time, reconstruction matrix size of 512×512, slice thickness, and increment
of 1.0 mm, using standard (soft) and hard kernel filters. Imaging exams were
independently evaluated by two thoracic radiologists (MKS and DTW), blinded to
clinical data, laboratory, and pathology results as described [26]. Divergences were
solved by consensus. All CXRs available were classified for the presence and grade
of viral pneumonia [27]. Pulmonary disease evolution on imaging was evaluated
considering all exams from the initial to the last image before death. Tomographic
images were evaluated similarly to CXR images.

Statistical Analysis
For puncta quantification, all histological sections were viewed on a 63x objective
for digitalizing random images using the LSM 780 system in the Axio Observer
microscope, covering an area of about ~1.7 mm^2 of lung parenchyma analyzed per
case. Manual counting of puncta and cells was blinded and performed using the
acquired images. Morphometric analyzes were performed as described [28]. The
quantification of expression by immunohistochemistry was performed by calculating
the percentage of marked area, the scanned images were opened in the ImageJ
software, using the IHQ Toolbox plugin, which consists of a semi-automatic color
selection tool that selects the pixels positive for immunohistochemical marking,
differentiating them from background and H&E marking, after selecting the positive
pixels, the images were transformed into 8-bits and the area occupied by these
tones was calculated. The distribution of the gene expression and biochemical
marker and puncta count data was evaluated using the Shapiro–Wilk test; the data
were analyzed using non-parametric Kruskal-Wallis, Mann-Whitney test and
Spearman correlation. Data were presented in graphs with mean and standard
deviation. Statistical analyzes were performed using the GraphPad PRISM 5.0
program, with $p < 0.05$ being considered statistically significant. Heatmaps were
constructed using the heatmap.2 function in the R program (Project for Statistical
Computing, version 3.4.1).

Results

***Lethal cases of COVID-19 develop severe acute respiratory distress syndrome
(ARDS) and higher inflammasome activation in the lung parenchyma than
influenza patients***

We evaluated inflammasome activation in the lung parenchyma of 47 patients who
died from SARS-CoV-2 infection from April to July 2020. These patients were
infected with the ancestral strain of SARS-CoV-2 before the development of the
COVID-19 variants of concern and before the use of vaccinations. We also
evaluated 12 patients who died from influenza before the COVID-19 pandemic. As a
noninfected control, we evaluated inflammasome activation in biopsies of the
benign area of the lungs from patients who died due to lung adenocarcinoma. The
data in **Table 1** show the demographic and clinical characteristics of the influenza
and COVID-19 patients. COVID-19 patients had a higher mean age (67.97 years)
than influenza patients (41.5 years). Most of the influenza patients were infected
with subtype A H1N1 (41.66%) but also with subtypes A H3N2 (16.66%) and B
(16.66%). In addition, according to the data observed in the COVID-19 cases that
occurred in 2020 (patients infected with the ancestral Wuhan strain of SARS-CoV-
2), we found that COVID-19 patients had a higher frequency of comorbidities, such
as hypertension, in addition to having (on average) grade 1 obesity (BMI: 31.10).
Furthermore, patients with influenza and COVID-19 (on average) exhibited altered
values of CRP, D-dimers, LDH, creatinine, urea, AST, ALT, PT (INR), and blood
glucose levels. Moreover, patients with influenza presented with a fulminant picture
of ARDS and died (on average) less than 24 hours after seeking health services. In
contrast, patients with COVID-19 had an average illness time of 18 days, and the
vast majority (76.59%) of the patients used MV, with an average of 12.38 days of
use of mechanical ventilation. Moreover, COVID-19 patients had a more severe
respiratory condition than influenza patients, with a considerably altered PaO_2 and
PaO_2/FiO_2 characterizing a moderate to severe ARDS condition (**Table 1**).
Consistent with the respiratory statuses of the patients, the histopathological
analyses of COVID-19 patients demonstrated a higher fibrotic phase of DAD, OP,
and pneumonitis than those of influenza patients (**Figure 1A-C**). To analyze
histological features of patients' lungs, we measured the lung parenchyma area in
the histological sections. In support of the data described above, we observed that

patients who died from SARS-CoV-2 and influenza had a much larger area of lung parenchyma than adenocarcinoma patients, but no difference was found in influenza versus COVID-19, thus supporting the idea that both viral infections trigger robust inflammatory infiltration to the lung in severe cases of the disease (**Figure 1D-G**). These data are in agreement with histopathological findings showing an intense inflammatory process in patients who died from SARS-CoV-2 and influenza [3, 29].

To assess inflammasome activation in the lungs of COVID-19 and influenza patients, the lung parenchyma area and cell count were scanned in histological sections by using 2-photon microscopy. The parenchyma area was calculated by using ImageJ software, and inflammasome activation was microscopically scored by the presence of characteristic NLRP3 or ASC puncta/specks [30]. The parenchyma area was used to normalize all of the counts between the patients. Inflammasome activation was quantified by counting ASC and NLRP3 puncta in the lung tissue of these patients. We observed that patients with SARS-CoV-2 infection had more ASC and NLRP3 puncta than patients with influenza and controls with lung adenocarcinoma (**Figure 1H, J**). Representative images of ASC and NLRP3 puncta in the patients' lungs are shown (**Figures 1I, K**). We observed ASC colocalization in nearly all of the scored NLRP3 puncta, thus confirming that these puncta structures that were abundantly found in the patients' lungs are indeed the NLRP3/ASC inflammasome (**Figure 1L, M**). Collectively, these data indicate that COVID-19 patients have higher inflammasome activation than influenza patients and that these patients evolved to a fibrotic phase of DAD, OP, and pneumonitis.

The cellular profile of inflammasome activation differs in lethal cases of COVID-19 and influenza

To comprehensively investigate the cell types operating during influenza and SARS-CoV-2 infection, we analyzed the presence of macrophages (CD64$^+$), endothelial cells (CD34$^+$), type 1 pneumocytes (PDPN$^+$, Podoplanin$^+$), and type 2 pneumocytes (SFTPC$^+$) in the lungs of patients who died from SARS-CoV-2 infection and influenza. We found that total counts of macrophages and endothelial cells were not different between COVID-19 and influenza patients and were also similar to those observed in the benign area of lung adenocarcinoma (**Figure 2A, 2B**). However, we observed that patients who died from influenza had fewer type 1 pneumocytes and type 2 pneumocytes (**Figure 2C, 2D**), which is consistent with data indicating that the influenza virus preferentially infects type 1 and type 2 pneumocytes than macrophages and promotes the death of these cells due to the viral replication process [31]. Next, we evaluated the participation of specific cells in inflammasome activation by scoring ASC and NLRP3 puncta in macrophages (CD64$^+$), endothelial cells (CD34$^+$), type 1 pneumocytes (PDPN$^+$), and type 2 pneumocytes (SFTPC$^+$). We observed that in the lungs of COVID-19 patients, both ASC and NLRP3 puncta were more frequently found in macrophages (**Figure 2E, I**) and endothelial cells (**Figure 2F, J**) than in influenza patients. In contrast, in the assessment of type 1 and type 2 pneumocytes, we found that ASC and NLRP3 puncta were more frequently observed in the lungs of influenza patients than in COVID-19 patients (**Figure 2G, H, K, L**). Representative images of ASC and NLRP3 puncta in macrophages, endothelial cells, and type 1 and type 2 pneumocytes are shown in **Figure 2M-T**. Together, these data demonstrate for the first time that distinct pulmonary cell types can trigger inflammasome activation in COVID-19 and influenza; additionally, the data indicate a main contribution of macrophages and endothelial cells to inflammasome activation during SARS-CoV-2 and type I and II pneumocytes to inflammasome activation during influenza. The magnitude of inflammasome activation and the different cellular profiles of inflammasome activation between COVID-19 and influenza may contribute to explaining the overall increased inflammasome activation found in COVID-19 compared to influenza.

Subsequently, we performed immunohistochemistry analyses of the lung

parenchyma to assess the expression of inflammasome components and observed

variable expression of NLRP3, ASC, cleaved GSDMD, IL-1β, and caspase-1 in

COVID-19 and influenza (**Supplementary Fig. 1A-E**). To assess which lung

parenchyma cells expressed these inflammasome components, we evaluated the

expression of ASC, NLRP3, caspase-1, cleaved GSDMD, and IL-1β on endothelial

cells (CD34⁺), macrophages (CD68⁺), and type 2 pneumocytes (SFTPC⁺) via

immunohistochemistry (**Supplementary Fig. 1F-H**). We also stained these tissues

with anti-Spike of SARS-CoV-2 and found that virus-associated endothelial cells,

macrophages, and type 2 pneumocytes expressed ASC, NLRP3, Caspase-1, and

IL-1β (**Supplementary Fig. 1F-H**).

Disease progression in lethal cases of COVID-19 occurs with decreasing viral

load and increasing inflammasome activation over time in the lung

parenchyma

To assess whether inflammasome activation was associated with specific patient

clinical conditions, we performed Pearson's correlations in COVID-19 patients. Even

though all of these patients died, we observed a strong negative correlation

between viral load and the extent of the disease (**Figure 3A, B**). In addition, we

observed a positive correlation between the amount of NLRP3 and ASC puncta with

the time of disease (**Figure 3C, D**), thus suggesting that, in general, whereas the

viral load is reduced, inflammasome activation increases during hospitalization in

these lethal cases of COVID-19. We also observed significant negative correlations

between NLRP3 puncta and PaO_2/FiO_2 (**Figure 3E**), thus suggesting that

inflammasome activation is related to an overall worsening pulmonary function. We

detected no statistically significant correlations between NLRP3 or ASC puncta and

viral load in the tissues (**Supplementary Fig. 2**).

Inflammasome activation and pulmonary viral loads defines two distinct

clinical outcomes in lethal cases of COVID-19.

The imbalance of inflammatory and anti-inflammatory processes leads to an

excessive release of cytokines into the systemic circulation with potentially

deleterious consequences, including systemic inflammatory response syndrome

(SIRS), circulatory shock, multiorgan dysfunction syndrome (MODS), and death [32]. Several studies have reported the association of influenza [33-37] and SARS-CoV-2 [38-40] with hyperinflammatory syndrome related to disease severity, and inflammasome activation may be associated with Cytokine Release Syndrome (CRS) [41-43]. Thus, to correlate inflammasome activation with the hyperinflammatory profile observed in lethal cases of COVID-19, we analyzed the expression of genes related to the inflammatory process and inflammasome activation. We evaluated gene expression in the lungs of COVID-19 patients and observed that several inflammatory cytokine genes have a positive correlation with the genes involved in inflammasome activation (**Supplementary Fig. 3A**). We did not observe a significant difference in the expression of these genes when we compared COVID-19 patients with lung adenocarcinoma patients (**Supplementary Fig. 3B-U**), possibly due to the large dispersion of data observed in COVID-19 patients. Due to this dispersion and high variation in gene expression detected in COVID-19 patients, we performed an unsupervised heatmap constructed with data from relative gene expression and revealed the formation of two clusters in COVID-19 patients (**Figure 4A**). Cluster 1 was characterized by a higher viral load and lower expression of inflammasome and inflammatory genes. In contrast to Cluster 1, Cluster 2 was comprised of patients who died with a lower viral load and increased expression of inflammasome and inflammatory genes (**Figure 4A**). To gain insights into key differences between these two clusters, we analyzed PaO_2/FiO_2 and A-a O_2 gradient kinetics in these patients. We observed that patients in Cluster 2, who had overall increased inflammation, had worsening pulmonary function compared to those in Cluster 1 (**Figure 4B, C**). By contrast, patients of Cluster 1 had disseminated intravascular coagulation (**Table 2**), according to the parameters recommended by the International Society of Thrombosis and Hemostasis (ISTH) [44]. Basic demographic information stratified by cluster is provided in **Table 2**. Strikingly, patients who belonged to Cluster 2 had a longer illness time (**Figure 4D**), worse pulmonary function (as indicated by the PaO_2/FiO_2 and A-a O_2 gradients) (**Figure 4E, F**), a larger area of pulmonary fibrosis (**Figure 4G**), and greater activation of the NLRP3 inflammasome, as measured by puncta formation (**Figure 4H**). Representative images of the lung parenchyma of three representative patients in Cluster 1 and three representative patients in Cluster 2 are shown in **Figure 4I-J**. In addition, we confirmed that patients belonging to Cluster 2 had an overall lower viral load than patients from Cluster 1 (**Supplementary Fig. 4A, B**). Next, we assessed radiological analyses of 16 patients from Cluster 1 and 31 patients from Cluster 2 by comparing the first and last chest X-ray images (CXR) and observed overall

worsening pulmonary conditions in patients from Cluster 2 (**Supplementary Fig.**

5A). Representative images of CXR of 2 patients from each cluster are shown in

Supplementary Fig. 5B, C. **Table 3** summarizes the general imaging evaluation

findings for the patients in Cluster 1 and Cluster 2. Taken together, our data suggest

the existence of two distinct groups of patients who succumbed to COVID-19, one

group, with lower viral loads, higher inflammation, increased fibrosis and worse

pulmonary conditions than the other group.

Discussion

Although SARS-CoV-2 and influenza share many similarities, including the

transmission, replication, and induction of similar clinical outcomes in humans,

COVID-19 can be significantly more severe in nonvaccinated individuals [45-48]. The

mechanisms underlying these differences are unknown, and the revelation that

exacerbated inflammasome activation mediates COVID-19 pathology [13, 14, 16] has

led to comparisons of inflammasome activation in COVID-19 patients with other

pulmonary viral diseases. Therefore, we assessed pulmonary samples of lethal

cases of COVID-19 and influenza and determined the cellular profile of

inflammasome activation in patients' lungs. Lethal cases of COVID-19 exhibited an

overall greater inflammasome activation, in addition to having a different cellular

activation profile, compared to lethal cases of influenza. This different profile of

inflammasome activation can be partially explained by the tropism of each virus.

Whereas the influenza virus almost exclusively infects pneumocytes, with minor

involvement of macrophages, SARS-CoV-2 associates with a broad range of

immune cells, including macrophages and structural cells, such as type 2

pneumocytes, club-like cells, goblet cells, and endothelial cells [31, 49-52]. Thus, it is

possible that the large number of cell types that can be infected by SARS-CoV-2

may be a determining factor for the increased activation of the inflammasome

observed in fatal cases of COVID-19 compared to influenza viruses. In addition,

reduced inflammasome activation in influenza patients can be partially explained by

the NS1 protein of the influenza A virus, which inhibits the NLRP3 inflammasome by

suppressing ASC ubiquitination [53]. Moreover, whereas a protective role of the

inflammasome has never been reported for COVID-19, these platforms account for

protective antiviral immunity against influenza infection [54, 55]. Therefore, it is possible

that influenza patients with higher inflammasome activation undergo a resolution of

infection; as a result, these patients do not seek hospitalizations, as often occurs

with COVID-19 patients.

Macrophages are possibly the most effective cell types that trigger inflammasome

activation [56]; according to this information, our data showed that macrophages in

the lungs of COVID-19 and influenza patients are effectively infected and strongly

induce inflammasome activation. These data are in agreement with previously

published articles indicating high levels of viral RNA in lung monocytes and macrophages of COVID-19 patients [57, 58], as well as pronounced inflammasome activation in macrophages from COVID-19 patients [13, 14, 16]. In contrast, the influenza virus, which effectively replicates in type I and type II pneumocytes, promotes exacerbated inflammasome activation and the depletion of these cells in the lungs of fatal cases of influenza. It is possible that the inflammasome and pyroptosis of type I and II pneumocytes during influenza infection contribute to the clinical symptoms and clinical outcomes of this disease. Importantly, this appears to be the first report of inflammasome activation in type 1 and type 2 pneumocytes in the lung, as the description of inflammasome activation in pneumocytes was previously restricted to the A549 cell lineage [59-61]. Remarkably, inflammasome activation in pneumocytes is more pronounced in patients infected with the influenza virus. It is possible that inflammasome activation in pneumocytes is favored by influenza virus tropism in these cells [31, 49].

In addition to inflammasome activation in pneumocytes, the analysis of inflammasome activation in different pulmonary cell types indicates that endothelial cells exposed to SARS-CoV-2 express inflammasome proteins and contain active NLRP3/ASC puncta, thus demonstrating inflammasome activation. Despite reports indicating that endothelial cells are not productively infected by SARS-CoV-2 [62], precursors of hematopoietic and endothelial cells stimulated with SARS-CoV-2 spike protein increase the expression of *AIM2*, *NLRP1*, *NLRP3*, *IL1B*, and *ASC* and trigger caspase-1 activation [63, 64]. In addition, inflammasome activation in endothelial cells has been previously reported [65-68]. These observations are consistent with our data indicating the expression of inflammasome components and inflammasome activation in CD34+ cells in the lungs of COVID-19 patients. Although these cells were stained positive for the SARS-CoV-2 spike protein, it is unknown whether infection and viral replication are required for inflammasome activation in these cells. It is possible that spike stimulation is sufficient for inflammasome activation, which is a feature that would explain reports indicating damage and dysfunction of these cells during COVID-19 and the characterization of COVID-19 as an endothelial disease [69-74]. It is important to highlight the fact that the vascular endothelium is actively involved in the regulation of inflammation and thrombus formation. This is particularly important in COVID-19 because the interplay between inflammasome activation in macrophages and the endothelium can lead to pyroptotic macrophages releasing tissue factor (TF), which is an

essential initiator of coagulation cascades that are frequently observed in severe

cases of COVID-19 [75-77]. These data support the association of inflammasomes with

the coagulopathy that is observed in COVID-19.

Regardless of the cell type involved in inflammasome activation and comparisons

with influenza, our robust analysis of 47 COVID-19 patients allowed for the

classification of the patients into two groups. Cluster 2, which was composed of 31

patients, demonstrated remarkably high inflammasome activation and expression of

inflammatory genes with increased fibrosis in patients' lungs. Inflammatory

cytokines released upon inflammasome activation have been previously linked to

the development of pulmonary fibrosis [78-83]. In addition, cytokines such as IL-1β, IL-

18, and IL-1α have been described as triggering the activation of fibroblasts and

stimulating the synthesis and accumulation of type I collagen, TIMP, collagenase,

and PGE2 [78, 84], which may contribute to the triggering of the deleterious effects of

inflammasomes in patients' lungs.

Our findings showed that the viral load in the lungs of COVID-19 patients is

inversely proportional to the duration of the disease, as has been suggested in

previous studies [85, 86]. In addition, we collected data indicating that increased illness

time is associated with increased inflammasome activation, and a reduced viral load

implies a dysregulated immune response in which inflammation persists, whereas

the viral load declines. In this context, it is possible that inflammasome activation in

these patients occurs not as a result of the viral infection itself but by the presence

of damage-associated molecular patterns that are generated during the

inflammatory process. We also tested whether the mechanical ventilation used in

COVID-19 patients would interfere with inflammasome activation. This hypothesis is

supported by data indicating that mechanical ventilation-induced hyperoxia can

induce potassium efflux through the P_2X_7 receptor, thus leading to inflammasome

activation and the secretion of proinflammatory cytokines [43, 87-91]. However, when

we separated the COVID-19 patients into two groups according to the use or non-

use of mechanical ventilation, we detected no differences in histopathological

analyses and inflammasome activation (**Table 4**). Moreover, we confirmed that

patients who underwent mechanical ventilation had a longer illness time, higher

hypertension, less CRP and albumin, higher amounts of urea, and worsened

pulmonary function (according to the PaO2/FiO2 and A-an O2 gradients). Thus, our

data do not support the hypothesis that mechanical ventilation is directly associated

with inflammasome activation. Nonetheless, we demonstrated (for the first time) a

cellular profile of inflammasome activation in the lungs of patients who died from

COVID-19 and influenza. Importantly, the identification of two distinct profiles in

lethal cases of COVID-19 (which revealed the balance of viral loads versus

inflammasome-mediated pulmonary inflammation) will be critical for decisions

between immune-mediated or antiviral-mediated therapies for the treatment of

critical cases of COVID-19.

Acknowledgments: We would like to thank Maira Nakamura, Amanda Zuin and Dr.

Roberta Sales for technical support.

Funding: Fundação de Amparo à Pesquisa do Estado de Sao Paulo, FAPESP

grants 2013/08216-2, 2019/11342-6 and 2020/04964-8. Conselho Nacional de

Desenvolvimento Científico e Tecnológico, CNPq grant 303021/2020-9.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES grant

88887.507253/2020-00.

Competing interests: Authors declare that they have no competing interests.

References

1. Centers for Disease Control and Prevention , N.C.f.I.a.R.D.N. (2021).
2. WHO (World Health Organization, https://covid19.who.int/; 2020).
3. Batah, S.S. & Fabro, A.T. Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. *Respir Med* **176**, 106239 (2021).
4. Bösmüller, H., Matter, M., Fend, F. & Tzankov, A. The pulmonary pathology of COVID-19. *Virchows Arch* **478**, 137–150 (2021).
5. Polak, S.B., Van Gool, I.C., Cohen, D., von der Thüsen, J.H. & van Paassen, J. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. *Mod Pathol* **33**, 2128-2138 (2020).
6. Allen, I.C. *et al.* The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. *Immunity* **30**, 556-565 (2009).
7. Boal-Carvalho, I. *et al.* Influenza A viruses limit NLRP3-NEK7-complex formation and pyroptosis in human macrophages. *EMBO Rep* **21**, e50421 (2020).
8. Ichinohe, T., Pang, I.K. & Iwasaki, A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. *Nat Immunol* **11**, 404-410 (2010).
9. Moriyama, M. *et al.* Influenza Virus-Induced Oxidized DNA Activates Inflammasomes. *iScience* **23**, 101270 (2020).
10. Thomas, P.G. *et al.* The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. *Immunity* **30**, 566-575 (2009).
11. Cama, V.F. *et al.* The microglial NLRP3 inflammasome is involved in human SARS-CoV-2 cerebral pathogenicity: A report of three post-mortem cases. *J Neuroimmunol* **361**, 577728 (2021).
12. Eisfeld, H.S. *et al.* Viral Glycoproteins Induce NLRP3 Inflammasome Activation and Pyroptosis in Macrophages. *Viruses* **13** (2021).
13. Junqueira, C. *et al.* FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. *Nature* (2022).
14. Sefik, E. *et al.* Inflammasome activation in infected macrophages drives COVID-19 pathology. *Nature* (2022).
15. Lucas, C.W., P. LKlein, J. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. *Nature* (2020).
16. Rodrigues, T.S. *et al.* Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. *J Exp Med* **218** (2021).
17. Kommoss, F.K.F. *et al.* The Pathology of Severe COVID-19-Related Lung Damage. *Dtsch Arztebl Int* **117**, 500-506 (2020).
18. Xu, Z. *et al.* Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* **8**, 420-422 (2020).
19. Sauter, J.L. *et al.* Insights into pathogenesis of fatal COVID-19 pneumonia from histopathology with immunohistochemical and viral RNA studies. *Histopathology* **77**, 915-925 (2020).
20. Toldo, S. *et al.* Inflammasome formation in the lungs of patients with fatal COVID-19. *Inflamm Res* **70**, 7-10 (2021).
21. Taubenberger, J.K. & Morens, D.M. The pathology of influenza virus infections. *Annu Rev Pathol* **3**, 499-522 (2008).
22. Glass, G., Papin, J.A. & Mandell, J.W. SIMPLE: a sequential immunoperoxidase labeling and erasing method. *J Histochem Cytochem* **57**, 899-905 (2009).
23. Lu, X. *et al.* US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis* **26**, 1654-1665 (2020).
24. Corman, V.M. *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin* **25** (2020).
25. Raghu, G. *et al.* Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *American journal of respiratory and critical care medicine* **198**, e44-e68 (2018).
26. Koenigkam-Santos, M. *et al.* SARS-Cov-2 pneumonia phenotyping on imaging exams of patients submitted to minimally invasive autopsy. *Ann Transl Med* **10**, 140 (2022).
27. Revel, M.P. *et al.* COVID-19 patients and the radiology department - advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI). *Eur Radiol* **30**, 4903-4909 (2020).
28. Weibel, E.R. Principles and methods for the morphometric study of the lung and other organs. *Lab Invest* **12**, 131-155 (1963).

29. Hariri, L.P. *et al.* Lung Histopathology in Coronavirus Disease 2019 as Compared With
Severe Acute Respiratory Sydrome and H1N1 Influenza: A Systematic Review. *Chest* **159**,
73-84 (2021).
30. Hauenstein, A.V., Zhang, L. & Wu, H. The hierarchical structural architecture of
inflammasomes, supramolecular inflammatory machines. *Current opinion in structural*
biology **31**, 75-83 (2015).
31. Weinheimer, V.K. *et al.* Influenza A viruses target type II pneumocytes in the human lung. *J*
Infect Dis **206**, 1685-1694 (2012).
32. Sinha, P., Matthay, M.A. & Calfee, C.S. Is a "Cytokine Storm" Relevant to COVID-19?, in
JAMA Intern Med, Vol. 180 1152-1154 (United States; 2020).
33. Peiris, J.S. *et al.* Re-emergence of fatal human influenza A subtype H5N1 disease. *Lancet*
363, 617-619 (2004).
34. de Jong, M.D. *et al.* Fatal outcome of human influenza A (H5N1) is associated with high viral
load and hypercytokinemia. *Nat Med* **12**, 1203-1207 (2006).
35. Kash, J.C. *et al.* Genomic analysis of increased host immune and cell death responses
induced by 1918 influenza virus. *Nature* **443**, 578-581 (2006).
36. Cillóniz, C. *et al.* Lethal influenza virus infection in macaques is associated with early
dysregulation of inflammatory related genes. *PLoS Pathog* **5**, e1000604 (2009).
37. Kobasa, D. *et al.* Aberrant innate immune response in lethal infection of macaques with the
1918 influenza virus. *Nature* **445**, 319-323 (2007).
38. Qin, C. *et al.* Dysregulation of Immune Response in Patients With Coronavirus 2019
(COVID-19) in Wuhan, China. *Clin Infect Dis* **71**, 762-768 (2020).
39. Chen, H. *et al.* SARS-CoV-2 activates lung epithelial cell proinflammatory signaling and
leads to immune dysregulation in COVID-19 patients. *EBioMedicine* **70**, 103500 (2021).
40. Huang, K.J. *et al.* An interferon-gamma-related cytokine storm in SARS patients. *J Med Virol*
75, 185-194 (2005).
41. Olajide, O.A., Iwuanyanwu, V.U., Lepiarz-Raba, I. & Al-Hindawi, A.A. Induction of
Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a
Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.
Inflammation **44**, 1865-1877 (2021).
42. Cui, H. & Zhang, L. Key Components of Inflammasome and Pyroptosis Pathways Are
Deficient in Canines and Felines, Possibly Affecting Their Response to SARS-CoV-2
Infection. *Front Immunol* **11**, 592622 (2020).
43. Dolinay, T. *et al.* Inflammasome-regulated cytokines are critical mediators of acute lung
injury. *American journal of respiratory and critical care medicine* **185**, 1225-1234 (2012).
44. Taylor, F.B., Jr. *et al.* Towards definition, clinical and laboratory criteria, and a scoring
system for disseminated intravascular coagulation. *Thromb Haemost* **86**, 1327-1330 (2001).
45. Taniguchi, Y. *et al.* Comparison of patient characteristics and in-hospital mortality between
patients with COVID-19 in 2020 and those with influenza in 2017-2020: a multicenter,
retrospective cohort study in Japan. *Lancet Reg Health West Pac* **20**, 100365 (2022).
46. Fröhlich, G.M. *et al.* Hospital outcomes of community-acquired COVID-19 versus influenza:
Insights from the Swiss hospital-based surveillance of influenza and COVID-19. *Euro*
surveillance : bulletin Europeen sur les maladies transmissibles = European communicable
disease bulletin **27** (2022).
47. Godaert, L., Cebille, A., Proye, E. & Dramé, M. COVID-19 versus Seasonal Influenza:
Comparison of Profiles of Older Adults Hospitalized in a Short-Term Geriatric Ward in
France. *Am J Trop Med Hyg* **106**, 108-113 (2021).
48. Manzanares-Meza, L.D. & Medina-Contreras, O. SARS-CoV-2 and influenza: a comparative
overview and treatment implications. *Bol Med Hosp Infant Mex* **77**, 262-273 (2020).
49. Ogiwara, H. *et al.* Histopathological evaluation of the diversity of cells susceptible to H5N1
virulent avian influenza virus. *Am J Pathol* **184**, 171-183 (2014).
50. Ramos da Silva, S. *et al.* Broad Severe Acute Respiratory Syndrome Coronavirus 2 Cell
Tropism and Immunopathology in Lung Tissues From Fatal Coronavirus Disease 2019. *J*
Infect Dis **223**, 1842-1854 (2021).
51. Bhatnagar, J. *et al.* Evidence of Severe Acute Respiratory Syndrome Coronavirus 2
Replication and Tropism in the Lungs, Airways, and Vascular Endothelium of Patients With
Fatal Coronavirus Disease 2019: An Autopsy Case Series. *J Infect Dis* **223**, 752-764 (2021).
52. Pei, R. *et al.* Host metabolism dysregulation and cell tropism identification in human airway
and alveolar organoids upon SARS-CoV-2 infection. *Protein Cell* **12**, 717-733 (2021).
53. Park, H.S. *et al.* NS1 Protein of 2009 Pandemic Influenza A Virus Inhibits Porcine NLRP3
Inflammasome-Mediated Interleukin-1 Beta Production by Suppressing ASC Ubiquitination.
J Virol **92** (2018).
54. Ichinohe, T., Lee, H.K., Ogura, Y., Flavell, R. & Iwasaki, A. Inflammasome recognition of
influenza virus is essential for adaptive immune responses. *J Exp Med* **206**, 79-87 (2009).
55. Schmitz, N., Kurrer, M., Bachmann, M.F. & Kopf, M. Interleukin-1 is responsible for acute
lung immunopathology but increases survival of respiratory influenza virus infection. *J Virol*
79, 6441-6448 (2005).

56. Broz, P. & Dixit, V.M. Inflammasomes: mechanism of assembly, regulation and signalling.
Nat Rev Immunol **16**, 407-420 (2016).
57. Delorey, T.M. *et al.* COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular
targets. *Nature* **595**, 107-113 (2021).
58. Pontelli, M.C. *et al.* SARS-CoV-2 productively infects primary human immune system cells in
vitro and in COVID-19 patients. *J Mol Cell Biol* (2022).
59. Ji, J., Hou, J., Xia, Y., Xiang, Z. & Han, X. NLRP3 inflammasome activation in alveolar
epithelial cells promotes myofibroblast differentiation of lung-resident mesenchymal stem
cells during pulmonary fibrogenesis. *Biochim Biophys Acta Mol Basis Dis* **1867**, 166077
(2021).
60. Furukawa, S., Matsuda, K., Sugano, M., Uehara, T. & Honda, T. NLRP3 upregulation in
A549 cells co-cultured with THP-1 macrophages under hypoxia via deregulated TGF-β
signaling. *Exp Cell Res* **383**, 111506 (2019).
61. Wang, Y. *et al.* Activation of NLRP3 inflammasome enhances the proliferation and migration
of A549 lung cancer cells. *Oncol Rep* **35**, 2053-2064 (2016).
62. Schimmel, L. *et al.* Endothelial cells are not productively infected by SARS-CoV-2. *Clin
Transl Immunology* **10**, e1350 (2021).
63. Ratajczak, M.Z. *et al.* SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small
CD45(-) Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike
Protein Activates the Nlrp3 Inflammasome. *Stem Cell Rev Rep* **17**, 266-277 (2021).
64. Kucia, M. *et al.* An evidence that SARS-Cov-2/COVID-19 spike protein (SP) damages
hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome-
dependent manner. *Leukemia*, 1-4 (2021).
65. Xiang, M. *et al.* Hemorrhagic shock activation of NLRP3 inflammasome in lung endothelial
cells. *J Immunol* **187**, 4809-4817 (2011).
66. Xu, P. *et al.* Hemorrhagic shock augments Nlrp3 inflammasome activation in the lung
through impaired pyrin induction. *J Immunol* **190**, 5247-5255 (2013).
67. Yang, J. *et al.* Hemorrhagic shock primes for lung vascular endothelial cell pyroptosis: role in
pulmonary inflammation following LPS. *Cell Death Dis* **7**, e2363 (2016).
68. Paul, O. *et al.* Vascular Inflammation in Lungs of Patients with Fatal Coronavirus Disease
2019 (COVID-19) Infection: Possible role for the NLRP3 inflammasome. *medRxiv* (2021).
69. Hottz, E.D. *et al.* Platelet activation and platelet-monocyte aggregate formation trigger tissue
factor expression in patients with severe COVID-19. *Blood* **136**, 1330-1341 (2020).
70. Varga, Z. *et al.* Endothelial cell infection and endotheliitis in COVID-19. *Lancet* **395**, 1417-
1418 (2020).
71. Liu, J. *et al.* SARS-CoV-2 cell tropism and multiorgan infection, in *Cell Discov*, Vol. 7 17
(2021).
72. Nuovo, G.J. *et al.* Endothelial cell damage is the central part of COVID-19 and a mouse
model induced by injection of the S1 subunit of the spike protein. *Annals of diagnostic
pathology* **51**, 151682 (2021).
73. Ward, S.E. *et al.* Von Willebrand factor propeptide in severe coronavirus disease 2019
(COVID-19): evidence of acute and sustained endothelial cell activation. *Br J Haematol* **192**,
714-719 (2021).
74. Libby, P. & Lüscher, T. COVID-19 is, in the end, an endothelial disease. *Eur Heart J* **41**,
3038-3044 (2020).
75. Wu, C. *et al.* Inflammasome Activation Triggers Blood Clotting and Host Death through
Pyroptosis. *Immunity* **50**, 1401-1411.e1404 (2019).
76. Campos, J. *et al.* Neutrophil extracellular traps and inflammasomes cooperatively promote
venous thrombosis in mice. *Blood Adv* **5**, 2319-2324 (2021).
77. Zhang, Y. *et al.* Inflammasome activation promotes venous thrombosis through pyroptosis.
Blood Adv **5**, 2619-2623 (2021).
78. Hussain, S. *et al.* Inflammasome activation in airway epithelial cells after multi-walled carbon
nanotube exposure mediates a profibrotic response in lung fibroblasts. *Part Fibre Toxicol* **11**,
28 (2014).
79. Meng, Y. *et al.* The angiotensin-converting enzyme 2/angiotensin (1-7)/Mas axis protects
against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-
mediated RhoA/Rho kinase pathway. *Antioxid Redox Signal* **22**, 241-258 (2015).
80. Meng, Y. *et al.* Autophagy Attenuates Angiotensin II-Induced Pulmonary Fibrosis by
Inhibiting Redox Imbalance-Mediated NOD-Like Receptor Family Pyrin Domain Containing 3
Inflammasome Activation. *Antioxid Redox Signal* **30**, 520-541 (2019).
81. Sun, B. *et al.* Repetitive Dosing of Fumed Silica Leads to Profibrogenic Effects through
Unique Structure-Activity Relationships and Biopersistence in the Lung. *ACS Nano* **10**,
8054-8066 (2016).
82. Cho, S.J. *et al.* GLUT1-dependent glycolysis regulates exacerbation of fibrosis via AIM2
inflammasome activation. *Thorax* **75**, 227-236 (2020).

83.   Lv, Z. *et al.* NLRP3 Inflammasome Activation Contributes to Mechanical Stretch-Induced
762   Endothelial-Mesenchymal Transition and Pulmonary Fibrosis. *Crit Care Med* **46**, e49-e58
763   (2018).
764   84.   Postlethwaite, A.E. *et al.* Modulation of fibroblast functions by interleukin 1: increased
765   steady-state accumulation of type I procollagen messenger RNAs and stimulation of other
766   functions but not chemotaxis by human recombinant interleukin 1 alpha and beta. *J Cell Biol*
767   **106**, 311-318 (1988).
768   85.   Walsh, K.A. *et al.* SARS-CoV-2 detection, viral load and infectivity over the course of an
769   infection. *J Infect* **81**, 357-371 (2020).
770   86.   Desai, N. *et al.* Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2
771   Pulmonary Infection. *medRxiv* (2020).
772   87.   Jones, H.D. *et al.* The NLRP3 inflammasome is required for the development of hypoxemia
773   in LPS/mechanical ventilation acute lung injury. *Am J Respir Cell Mol Biol* **50**, 270-280
774   (2014).
775   88.   Zhang, Y., Liu, G., Dull, R.O., Schwartz, D.E. & Hu, G. Autophagy in pulmonary
776   macrophages mediates lung inflammatory injury via NLRP3 inflammasome activation during
777   mechanical ventilation. *Am J Physiol Lung Cell Mol Physiol* **307**, L173-185 (2014).
778   89.   Kuipers, M.T. *et al.* Ventilator-induced lung injury is mediated by the NLRP3 inflammasome.
779   *Anesthesiology* **116**, 1104-1115 (2012).
780   90.   Kolliputi, N., Shaik, R.S. & Waxman, A.B. The inflammasome mediates hyperoxia-induced
781   alveolar cell permeability. *J Immunol* **184**, 5819-5826 (2010).
782   91.   Wu, J. *et al.* Activation of NLRP3 inflammasome in alveolar macrophages contributes to
783   mechanical stretch-induced lung inflammation and injury. *J Immunol* **190**, 3590-3599 (2013).

 Table 1. Influenza and COVID-19 patients characteristics

Demographic Characteristics	Influenza Mean (±SD) or N (%)	SARS-CoV-2 Mean (±SD) or N (%)	p value
N	12	47	
Sex			
Female	4 (33.33%)	23 (48.93%)	0.5177*
Male	8 (66.66%)	24 (51.06%)	
Age (years)	41.5 (15.24±)	67.97 (15.05±)	<0.0001**
Illness Time (days)	-	18.08 (11.04±)	-
ICU	4 (33.33%)	37 (78.72%)	0.0045*
Influenza A (H1N1)	5 (41.66%)	-	-
Influenza A (H3N2)	2 (16.66%)	-	-
Influenza A not subtyped	3 (25.00%)	-	-
Influenza B	2 (16.66%)	-	-
Comorbidities			
Hypertension	2 (16.66%)	26 (55.32%)	0.0233*
BMI	-	31.10 (±8.82)	-
Diabetes	3 (25.00%)	18 (38.29%)	0.5092*
History of smoking	0 (0.00%)	12 (25.53%)	0.1012*
Heart disease	2 (16.66%)	12 (25.53%)	0.7119*
Lung disease	1 (8.33%)	12 (25.53%)	0.2679*
Kidney disease	0 (0.00%)	7 (14.89%)	0.3255*
History of stroke	0 (0.00%)	7 (14.89%)	0.3255*
Autoimmune diseases	0 (0.00%)	2 (4.25%)	>0.9999*
Laboratorial findings			
CRP (mg/dL)	22.55 (±12.66)	11.40 (±8.49)	0.0061**
D-Dimers (µg/mL)	-	4.91 (±4.46)	-
LDH (mmol/L)	5.18 (±3.91)	5.01 (±5.24)	0.9443**
Creatinine (mg/dL)	4.59 (±2.41)	2.22 (±1.4)	0.0008**
Urea (mg/dL)	140 (±64.07)	119.40 (±58.47)	0.4247**
AST (IU/L)	228 (±235.06)	104.42 (±90.74)	0.0174**
ALT (IU/L)	38.2 (±32.12)	72.12 (±55.14)	0.2012**
AST/ALT	3.99 (±2.66)	1.8 (±1.60)	0.0115**
PT (INR)	1.44 (±0.65)	1.81 (±2.13)	0.6765**
Albumin (g/dL)	3.02 (±1.36)	3.09 (±0.58)	0.8327**
Blood Glucose (mg/dL)	181.2 (±105.58)	194.72 (±94.60)	0.7656**
Respiratory status			
Temperature (ºC)	38.14 (±2.58)	37.39 (±1.73)	0.3833**
Mechanical ventilation	-	36 (76.59%)	-
Nasal-cannula oxygen	4 (33.33%)	11 (23.40%)	>0.9999*
Intubated time (days)	0.30 (±0.57)	12.38 (±7.14)	0.0004**
P_aO_2 (mmHg)	103.61 (±35.98)	74.01 (±24.63)	0.0112**
Venous saturation (S_vO_2)	74.54 (±9.23)	67.58 (±25.34)	0.5477**
P_aO_2/FiO_2[#]	476.85 (±257.13)	159.69 (±90.84)	<0.0001**
A-a O_2 Gradient Value[#]	157.73 (±294.00)	283.22 (±208.31)	0.3988**
Respiratory Rate (mov/min)	24.40 (±9.07)	26.55 (±6.80)	0.4764**
Histopathological findings			
Fibrosis (% of area)	1.66 (±5.77)	30.00 (±12.68)	<0.0001**
Organizing Pneumonia (% of area)	4.16 (±14.43)	10.74 (±14.89)	0.0437**
Acute Fibrinous and Organizing Pneumonia (% of area)	8.33 (±15.27)	6.91 (±12.49)	0.9052**
Diffuse Alveolar Damage (% of area)	37.5 (±37.44)	17.87 (±21.05)	0.1419**
Pneumonitis (% of area)	1.66 (±3.89)	22.57 (±15.34)	<0.0001**
Pulmonary infarction (% of area)	8.33 (±13.37)	3.404 (±9.618)	0.1363**

786   * Fisher's exact test; ** t-Test; # data after 18 days of hospitalization.

Table 2. COVID-19 (Cluster 1 and Cluster 2) patients characteristics

Demographic Characteristics	Cluster 1 Mean (±SD) or N (%)	Cluster 2 Mean (±SD) or N (%)	p value
N	16	31	-
Sex			
Female	6 (37.50%)	17 (54.83%)	0.358*
Male	10 (62.50%)	14 (45.16%)	
Age (years)	70.81 (±10.34)	66.5 (±17.46)	0.369**
Illness Time (days)	12.06 (±6.97)	21.19 (±9.64)	0.001**
ICU	11 (68.75%)	25 (80.64%)	0.471*
Comorbidities			
Hypertension	10 (62.50%)	16 (51.61%)	0.546*
BMI	28.39 (±6.92)	33.21 (±8.52)	0.057**
Diabetes	7 (43.75%)	11 (35.48%)	0.999*
History of smoking	4 (25.00%)	8 (25.80%)	0.999*
Heart disease	4 (25.00%)	8 (25.80%)	0.999*
Lung disease	3 (18.75%)	9 (29.03%)	0.505*
Kidney disease	1 (6.25%)	6 (19.35%)	0.395*
History of stroke	3 (18.75%)	4 (12.90%)	0.675*
Autoimmune diseases	1 (6.25%)	1 (3.22%)	0.999*
Laboratorial findings			
CRP (mg/dL)	11.54 (±1.64)	11.32 (±9.15)	0.924**
D-Dimers (µg/mL)	6.07 (±5.45)	4.38 (±3.91)	0.227**
LDH (mmol/L)	6.17 (±6.42)	4.41 (±4.52)	0.280**
Creatinine (mg/dL)	2.41 (±1.64)	2.12 (±1.21)	0.494**
Urea (mg/dL)	108.36 (±53.92)	125.09 (±60.75)	0.358**
AST (IU/L)	110.65 (±112.67)	101.08 (±78.69)	0.735**
ALT (IU/L)	72.40 (±59.92)	71.98 (±53.88)	0.980**
AST/ALT	2.1 (±2.47)	1.6 (±0.92)	0.319**
PT (INR)	1.56 (±0.98)	1.95 (±2.55)	0.560**
Albumin (g/dL)	3.24 (±0.65)	3.01 (±0.54)	0.251**
Blood Glucose (mg/dL)	191.00 (±100.25)	196.65 (±96.32)	0.851**
Respiratory status			
Temperature (ºC)	37.74 (±1.82)	37.20 (±1.62)	0.304**
Mechanical ventilation	11 (68.75%)	25 (80.64%)	0.471*
Nasal-cannula oxygen	5 (31.25%)	6 (19.35%)	0.471*
Intubated time (days)	8 (±4.72)	14.32 (±6.94)	0.009**
P_aO_2 (mmHg)	75.54 (±8.06)	73.27 (±1.69)	0.135**
Venous saturation (S_vO_2)	61.33 (±27.83)	70.59 (±19.27)	0.187**
P_aO_2/FiO_2[#]	216.16 (±32.94)	164.15 (±21.09)	<0.001**
A-a O_2 Gradient Value[#]	40.20 (±101.48)	237.58 (±68.05)	0.006**
Respiratory Rate (mov/min)	26.76 (±7.86)	26.45 (±5.75)	0.878**
Histopathological findings, vascular status and Inflammasome activation			
Fibrosis (% of area)	24.38 (±11.59)	32.90 (±14.05)	0.042**
Organizing Pneumonia (% of area)	23.30 (±18.16)	24.50 (±15.71)	0.815**
Acute Fibrinous and Organizing Pneumonia (% of area)	18.33 (±12.24)	23.89 (±15.76)	0.225**
Diffuse Alveolar Damage (% of area)	34.00 (±24.03)	33.33 (±20.23)	0.920**
Pneumonitis (% of area)	20.67 (±18.52)	23.86 (±15.88)	0.540**
Pulmonary infarction (% of area)	26.67 (±14.14)	20.00 (±14.14)	0.132**
Disseminated Intravascular Coagulation	8 (50.00%)	5 (16.13%)	0.0198*
NLRP3 puncta per parenchyma area (mm²)	143.67 (±89.00)	238.40 (±157.76)	0.031**

* Fisher's exact test; ** t-Test; # data after 18 days of hospitalization.

Table 3. Radiological Analyzes

	Cluster 1	Cluster 2	P value
Initial CXR pattern			
No opacities	1 (6.250%)	3 (9.67%)	0.9101
Mild viral pneumonia	2 (12.50%)	3 (9.67%)	
Moderate viral pneumonia	8 (50.00%)	12 (38.70%)	
Severe viral pneumonia	5 (31.25%)	11 (35.48%)	
Impaired analysis	0	2 (6.45%)	
Last CXR pattern			
No opacities	1 (6.25%)	2 (6.45%)	0.9971
Mild viral pneumonia	3 (18.75%)	5 (16.12%)	
Moderate viral pneumonia	6 (37.50%)	12 (38.70%)	
Severe viral pneumonia	4 (25.00%)	8 (25.80%)	
Impaired analysis	2 (12.50%)	4 (12.90%)	
Imaging evolution until death			
Improvement (fewer opacities)	5 (33.33%)	10 (32.25%)	0.0364
Stability	7 (46.66%)	4 (12.90%)	
Worsening (more opacities)	2 (13.33%)	12 (38.70%)	
Impaired analysis	1 (6.66%)	5 (16.12%)	
Disease Extent (Thoracic CT)			
0	0	0	0.0363
<25%	4 (66.66%)	1 (12.50%)	
25-50%	0	3 (37.50%)	
50-75%	1 (16.66%)	3 (37.50%)	
>75%	1 (16.66%)	1 (12.50%)	

Table 4. Characteristics of covid-19 patients who were submitted or not to mechanical ventilation (MV).

Demographics Characteristics	MV+ Mean (±SD) or N (%)	MV- Mean (±SD) or N (%)	p value
N	36	11	
Sex			
Female	17 (47.22%)	6 (54.54%)	0.7400*
Male	19 (52.77%)	5 (45.45%)	
Age (years)	65.61 (±13.52)	75.72 (±17.61)	0.0493**
Illness Time (days)	20.94 (±10.76)	8.72 (±5.40)	0.0007**
ICU	36 (100.00%)	0 (0.00%)	>0.9999*
Comorbidities			
Hypertension	23 (63.88%)	3 (27.27%)	0.0433*
BMI	30.61 (±8.52)	34.56 (±14.46)	0.4324**
Diabetes	16 (44.44%)	2 (18.18%)	0.1644*
History of smoking	11 (30.55%)	3 (27.77%)	>0.9999*
Heart disease	11 (30.55%)	1 (9.09%)	0.2440*
Lung disease	9 (25.00%)	2 (18.18%)	>0.9999*
Kidney disease	6 (16.66%)	1 (9.09%)	>0.9999*
History of stroke	4 (11.11%)	3 (27.77%)	0.3296*
Autoimmune diseases	1 (2.77%)	1 (9.09%)	0.4172*
Laboratorial findings			
CRP (mg/dL)	9.99 (±7.83)	16.02 (±9.29)	0.0377**
D-Dimers (μg/mL)	4.99 (±4.68)	4.56 (±3.62)	0.7989**
LDH (mmol/L)	5.78 (±5.76)	2.49 (±1.13)	0.0680**
Creatinine (mg/dL)	1.58 (±1.39)	1.05 (±0.50)	0.2242**
Urea (mg/dL)	138.18 (±54.07)	64.48 (±34.12)	0.0001**
AST (IU/L)	109.61 (±98.16)	84.81 (±54.14)	0.4725**
ALT (IU/L)	79.02 (±58.67)	45.38 (±26.97)	0.1254**
AST/ALT	1.6 (±1.74)	2.2 (±0.88)	0.3542**
PT (INR)	1.53 (±0.91)	2.82 (±4.24)	0.0900**
Albumin (g/dL)	2.99 (±0.54)	3.78 (±0.41)	0.0034**
Blood Glucose (mg/dL)	198.22 (±93.77)	181.11 (±102.34)	0.6340**
Respiratory status			
Temperature (ºC)	37.51 (±1.79)	36.99 (±1.53)	0.3890**
P_aO_2 (mmHg)	79.57 (±20.19)	53.99 (±24.12)	0.0014**
Venous saturation (S_vO_2)	70.86 (±14.36)	50.71 (±31.26)	0.0092**
P_aO_2/FiO_2[#]	132.63 (±67.94)	257.11 (±114.86)	<0.0001**
A-a O_2 Gradient Value[#]	351.09 (±183.40)	45.69 (±26.55)	<0.0001**
Respiratory Rate (mov/min)	27.61 (±6.17)	23.09 (±7.89)	0.0669**
Histopathological findings			
Fibrosis (% of area)	30.28 (±14.05)	29.09 (±12.21)	0.8015**
Organizing Pneumonia (% of area)	26.11 (±13.56)	20.00 (±11.54)	0.4520**
Acute Fibrinous and Organizing Pneumonia (% of area)	19.50 (±12.48)	26.00 (±15.16)	0.3906**
Diffuse Alveolar Damage (% of area)	28.82 (±19.34)	43.75 (±16.85)	0.0742**
Pneumonitis (% of area)	23.52 (±17.33)	20.00 (±8.16)	0.5435**
Pulmonary infarction (% of area)	25.00 (±10.00)	10.00 (±0.00)	0.2235**
Inflammasome activation			
NLRP3 puncta per parenchyma area (mm²)	204.3 (±155.5)	204.0 (±156.6)	0.9310**
ASC puncta per parenchyma area (mm²)	251.8 (±192.5)	267.3 (±133.1)	0.4196**

* Fisher's exact test; ** t-Test; # data after 18 days of hospitalization.

Figures and Figure Legends

Fig.1 - Sá et al.

Figure 1. Histopathological patterns and inflammasome activation in lung autopsy of COVID-19 and influenza patients. Histopathological analysis of lethal cases of COVID-19 and Influenza patients. (**A-G**) Histological analysis of hematoxylin and eosin (H&E) stained slides for the presence of fibrosis (**A**), organizing pneumonia (**B**) and pneumonitis (**C**). (**D-G**) Proportion of lung parenchyma area of COVID-19, Influenza and adenocarcinoma (benign area of the lungs) patients. (**E-G**) Representative images of H&E stain showing the lung parenchyma. Scale bars 200 µm. (**H-K**) Multiphoton microscopy analysis of lung autopsies of 47 COVID-19 patients, 12 influenza patients and 5 lung adenocarcinoma patients. Tissues were stained with anti-ASC (**H, I**) or anti-NLRP3 (**J, K**) for quantification of cells with inflammasome puncta in lung autopsies (in red, indicated by white arrows). DAPI stains cell nuclei (blue). Insets indicate a higher magnification of the indicated region (red rectangle). Scale bars 20 µm. (**L**) Percentage of NLRP3 and ASC puncta colocalization in the lungs of five COVID-19 patients. (**M**) Representative images showing ASC (green) and NLRP3 (red) colocalization. Scale bar 10 µm. Each dot in the figure represents the value obtained from each individual. *, $P < 0.05$ comparing the indicated groups, as determined by Mann-Whitney test (**A-D**) or by Kruskal-Wallis test (**H, J**). The images were acquired by multiphoton microscope using a 63x oil immersion objective and analyzed using ImageJ Software.

Fig.2- Sá et al.

Figure 2. Macrophages, endothelial cells, and pneumocytes contribute to

inflammasome activation in the lungs of COVID-19 patients and influenza.

Multiphoton microscopy analysis of lung autopsies of 47 COVID-19 patients, 12

influenza patients and 5 lung adenocarcinoma patients (benign area of the lungs). (**A-**

D) Numbers of macrophages (CD64$^+$, **A**), endothelial cells (CD34$^+$, **B**), type I

pneumocytes (PDPN$^+$, **C**) and type II pneumocytes (SFTPC$^+$, **D**) per lung parenchyma

area. (**E-L**) Percentage CD64$^+$ (**E, I**), CD34$^+$ (**F, J**), PDPN$^+$ (**G, K**) and SFTPC$^+$ (**H, L**)

containing ASC (**E-H**) or NLRP3 (**I-L**) puncta. Each dot in the figures represents the

value obtained from each individual. *, $P < 0.05$ comparing the indicated groups, as

determined by Kruskal-Wallis test. (**M-T**) Representative image of ASC (**M-P**) or

NLRP3 (**Q-T**) puncta (in red; indicated by white arrows) in CD64$^+$ (in red; **M, Q**), CD34$^+$

(in purple; **N, R**), PDPN$^+$ (in green; **O, S**) and SFTPC$^+$ (in green; **P, T**) cells from a lung

autopsy of a COVID-19 patient. DAPI stains cell nuclei (blue). Scale bars 10 μm. The

images were acquired by multiphoton microscopy using a 63x oil immersion objective

and analyzed using ImageJ Software.

Figure 3. Inflammasome activation positively correlates with disease time, and viral load inversely correlates with disease time. Spearman correlation of pulmonary viral load, inflammasome activation and illness time in 47 fatal COVID-19 patients. (**A**) Correlation of viral N2 with illness time; (**B**) Correlation of viral E with illness time; (**C**) Correlation of NLRP3 puncta per parenchyma area with illness time; (**D**) Correlation of ASC puncta per parenchyma area with illness time; (**E**) Correlation of NLRP3 puncta per parenchyma area with PaO_2/FiO_2. r and p-value are indicated in the figure.

Fig.4- Sá et al.

Figure 4. Pulmonary viral load and inflammatory gene expression defines two

patient clusters in lethal cases of COVID-19. (**A**) Heatmap of the mRNA expression

of inflammasome, inflammatory molecules/cytokines and viral N2 and E in lung

autopsies of 47 COVID-19 patients. PaO_2/FiO_2 (**B**) and A-a O_2 gradient (**C**) during

disease development of patients from Cluster 1 (N=16, green) and Cluster 2 (N=31,

red). *, $P < 0.05$ comparing the indicated groups, as determined by Area Under Curve

test. (**D-H**) Analysis of Cluster 1 and Cluster 2 for illness time (**D**), PaO_2/FiO_2 (**E**), A-a

O_2 gradient (**F**), fibrosis (**G**), and NLRP3 puncta per lung parenchyma area (**H**). Each

dot in the figure represents the value obtained from each individual. *, $P < 0.05$

comparing the indicated groups, as determined by Mann-Whitney test. (**I-J**)

Representative H&E images of lung parenchyma of 3 patients of cluster 1 (**I**) and 3

patients of cluster 2 (**J**). Scale bars 200 μm.

Supplementary Figures and Supplementary Figure Legends

Supplementary 1 - Sá et al.

Supplementary Fig. 1. Immunohistochemistry analysis of lung autopsies of

patients with COVID-19, influenza and lung adenocarcinoma.

Immunohistochemistry analysis of lung autopsies of 47 COVID-19 patients, 12

influenza patients and 5 lung adenocarcinoma patients (benign area of the lungs).

Quantification of percentage of area stained for ASC (**A**), NLRP3 (**B**), cleaved GSDMD

(**C**), IL-1β (**D**) and Caspase-1 (**E**). (**F-H**) Representative images of lungs from fatal

cases of COVID-19 and Influenza, indicating colocalization of viral Spike, ASC,

NLRP3, Caspase-1, IL-1β and cleaved GSDMD in endothelial cells (CD34$^+$, **F**),

macrophages (CD68$^+$, **G**), and type II pneumocytes (SFTPC$^+$, **H**).

Supplementary 2 - Sá et al.

Supplementary Fig. 2. Non-significant correlation or viral loads and inflammasome activation in lethal cases of COVID-19 patients. Spearman correlation of pulmonary viral load and inflammasome activation in 47 fatal COVID-19 patients. (**A**) Correlation of viral N2 with NLRP3 puncta per parenchyma area; (**B**) Correlation of viral E with NLRP3 puncta per parenchyma area; (**C**) Correlation of viral N2 with ASC puncta per parenchyma area; (**D**) Correlation of viral E with ASC puncta per parenchyma area. r and p-value are indicated in the figure.

Supplementary 3 - Sá et al.

Supplementary Fig. 3. Lung gene expression of COVID-19 patients. Correlation

matrix of inflammasome and inflammatory gene expression in lung autopsy of 47

COVID-19 patients (**A**). Colors indicate correlation scores, categorized as positive

strong correlation (r ≥ 0.70; red); moderate positive correlation (0.50 ≥ r ≤ 0.70;

orange); weak positive correlation (0.30 ≥ r ≤ 0.50; yellow); negative strong correlation

(r ≥ -0.70; dark blue); negative moderate correlation (-0.50 ≥ r ≤ -0.70; blue) or

negative weak correlation (-0.30 ≥ r ≤ -0.50; light blue). Only correlations with p<0.05

are represented in the correlation matrix. (**B-U**) Expression of mRNA in the lung

autopsies of COVID-19 patients and lung adenocarcinoma patients (benign area of the

lungs). Selected genes were *Il6* (**B**), *Il10* (**C**), *Il17* (**D**), *Ifna1* (**E**), *Ifnb1* (**F**), *Ifng* (**G**), *Il4*

(**H**), *Il2* (**I**), *Tnfa* (**J**), *Il1a* (**K**), *Il1b* (**L**), *Il18* (**M**), *I1ra* (**N**), *Nlrp3* (**O**), *Nlrc4* (**P**), *Nlrp1* (**Q**),

Aim2 (**R**), *Pycard* (**S**), *Casp1* (**T**), *Casp4* (**U**).

Supplementary 4 - Sá et al.

Supplementary Fig. 4. COVID-19 patients from Cluster 1 contains higher viral loads in the lungs as compared to patients from Cluster 2. Quantification of viral N2 (**A**) and E (**B**) in lung autopsies of 47 COVID-19 patients from Cluster 1 (N=16) and Cluster 2 (N=31). (**C**) Quantification of percentage of area stained for viral Spike protein in lung autopsies. Each dot in the figure represents the value obtained from each individual. *, $P < 0.05$ comparing the indicated groups, as determined by Mann-Whitney test. (**D-E**) Representative images of lungs tissues stained for Spike (red) and Hematoxylin (blue). Scale bars 100 μm.

Supplementary 5 - Sá et al.

A

Cluster 1
n=15

Cluster 2
n=31

Improvement (reduced opacities)
Stability
Worsening (increased opacities)
Impaired analysis

B

Cluster 1

Patient 1 - Moderate pneumonia - Stability

First CXR   Last CXR

Patient 2 - Mild pneumonia - Stability

First CXR   Last CXR

C

Cluster 2

Patient 1 - Severe pneumonia - Worsening

First CXR   Last CXR

Patient 2 - Severe pneumonia - Worsening

First CXR   Last CXR

Supplementary Fig. 5. CXR evolution of patients from Cluster 1 and Cluster 2.

Analysis of the first and last Chest x-radiography (CXR) of 46 COVID-19 patients

belonging from Cluster 1 (n=15) and Cluster 2 (n=31). (**A**) patients with reduced

opacities (green), stability (blue) and increased opacities (red) comparing the fists and

first CXR. Impaired analyses are shown in gray. Representative images of first and

last CXR from two patients from Cluster 1, indicating stability in moderate and mild

pneumonia (**B**) and two patients from Cluster 2, indicating worsening conditions in

cases of severe pneumonia (**C**).

Supplementary Table 1. The list of primer sequences for real time-PCR

Gene	Sequence of primer (5'- 3')
Human *Nlrp3*	F: GGACTGAAGCACCTGTTGTGCA
	R: TCCTGAGTCTCCCAAGGCATTC
Human *Il1a*	F: TGTATGTGACTGCCCAAGATGAAG
	R: AGAGGAGGTTGGTCTCACTACC
Human *Il1ra*	F: ATGGAGGGAAGATGTGCCTGTC
	R: GTCCTGCTTTCTGTTCTCGCTC
Human *Nlrc4*	F: AGGTCCCACAACTCGTCAAGCT
	R: TGCTCACACGATTTCCCGCCAA
Human *Pycard*	F: AGCTCACCGCTAACGTGCTGC
	R: GCTTGGCTGCCGACTGAGGAG
Human *Nlrp1*	F: ATTGAGGGCAGGCAGCACAGAT
	R: CTCCTTCAGGTTTCTGGTGACC
Human *Casp1*	F: GCTGAGGTTGACATCACAGGCA
	R: TGCTGTCAGAGGTCTTGTGCTC
Human *Aim2*	F: GCTGCACCAAAAGTCTCTCCTC
	R: CTGCTTGCCTTCTTGGGTCTCA
Human *Il6*	F: AGACAGCCACTCACCTCTTCAG
	R: TTCTGCCAGTGCCTCTTTGCTG
Human *Gapdh*	F: GTCTCCTCTGACTTCAACAGCG
	R: ACCACCCTGTTGCTGTAGCCAA
Human *Tnf Alpha*	F: CTCTTCTGCCTGCTGCACTTTG
	R: ATGGGCTACAGGCTTGTCACTC
Human *Il10*	F: TCTCCGAGATGCCTTCAGCAGA
	R: TCAGACAAGGCTTGGCAACCCA
Human *Il1b*	F: CCACAGACCTTCCAGGAGAATG
	R: GTGCAGTTCAGTGATCGTACAGG
Human *Il18*	F: GATAGCCAGCCTAGAGGTATGG
	R: CCTTGATGTTATCAGGAGGATTCA
Human *Casp4*	F: GGGATGAAGGAGCTACTTGAGG
	R: CCAAGAATGTGCTGTCAGAGGAC
Human *Il17a*	F: CGGACTGTGATGGTCAACCTGA
	R: GCACTTTGCCTCCCAGATCACA
Human *Ifng*	F: GAGTGTGGAGACCATCAAGGAAG
	R: TGCTTTGCGTTGGACATTCAAGTC
Human *Ifnb1*	F: CTTGGATTCCTACAAAGAAGCAGC
	R: TCCTCCTTCTGGAACTGCTGCA
Human *Ifna1*	F: AGAAGGCTCCAGCCATCTCTGT
	R: TGCTGGTAGAGTTCGGTGCAGA
Human *Il4*	F: CCGTAACAGACATCTTTGCTGCC
	R: GAGTGTCCTTCTCATGGTGGCT